Biocon receives EC marketing authorisation for pertuzumab biosimilar
Mumbai, Nov. 18 -- Biocon announced that the European Commission (EC) has granted marketing authorization for Pebrilzo(R), its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.